e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and automated evaluation; and GalOmic, a proprietary siRNA chemistry that generates potent and long-acting RNAi medicines. Its preclinical products are ETX-312 to treat metabolic dysfunction-associated steatohepatitis; ETX-407 for the treatment of dry age-related macular degeneration; and ETX-148 for the treatment of bleeding disorders. The company also develops ETX-291 to treat cardiometabolic disease; and ETX-258 for heart failure treatment. e-therapeutics plc was incorporated in 2001 and is based in London, the United Kingdom.